Vera Therapeutics
Logotype for Vera Therapeutics Inc

Vera Therapeutics (VERA) investor relations material

Vera Therapeutics 3rd Annual Guggenheim Healthcare Innovation Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Vera Therapeutics Inc
3rd Annual Guggenheim Healthcare Innovation Conference summary10 Nov, 2026

Commercial launch and market opportunity

  • TRUTAKNA launched in the U.S. on July 7; 700 Patient Start Forms were reported in the first 17 weeks, with strong early physician interest.

  • Starts came from community and academic practices, mainly among prevalent patients still showing abnormal lab values on background IgAN therapies, sometimes after TARPEYO.

  • At 17 weeks, sibeprenlimab had roughly 1,000 Patient Start Forms versus 700 for TRUTAKNA; both launches were growing, with little direct sales-force competition.

  • U.S. B-cell modulator opportunity in IgAN was estimated closer to $20B than $10B; three marketed players were expected by year-end, while estimated biopsy-proven U.S. IgAN prevalence was 160,000.

  • Final phase III efficacy analysis was presented at ASN and published in the New England Journal of Medicine; speakers said the data showed the class could reshape IgAN treatment.

Clinical profile and differentiation

  • Phase III results showed GFR on TRUTAKNA versus decline on placebo; no treated patients reached transplant, dialysis, or death versus seven on placebo.

  • Atacicept was described as having a placebo-like safety profile, supported by study in thousands of patients over many years; weekly dosing uses a small-volume, at-home auto-injector.

  • Nephrologists were said to be comfortable with weekly dosing; 82 field reps reportedly had not encountered weekly administration as a prescribing objection.

  • Payer strategy is to maintain parity access rather than pursue preferred status; branded step-throughs involving FILSPARI and VANRAFIA affect the B-cell class.

Development plans and expansion

  • European regulators were aligned on the current IgAN dataset, with a European filing planned for Q1 2027; similar progress was reported in Japan.

  • Monthly dose-range study data were expected in Q4 2026, comparing three monthly doses with weekly dosing; a weekly-to-monthly cohort was expected to read out after Q1 2027.

  • Dose selection will assess PK, PD, efficacy, and safety; priorities include preserving efficacy and safety with a single auto-injector injection.

  • PIONEER is studying a broad range of IgA-mediated disease, including advanced disease, vasculitis, pediatric and transplant patients, plus primary membranous nephropathy, FSGS, and minimal change disease.

  • In membranous nephropathy, week-four data showed lower anti-PLA2R antibody concentrations and reduced proteinuria; a novel development program is under consideration.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Vera Therapeutics earnings date

Logotype for Vera Therapeutics Inc
Q4 202626 Feb, 2027
Vera Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Vera Therapeutics earnings date

Logotype for Vera Therapeutics Inc
Q4 202626 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Vera Therapeutics, Inc. is a clinical-stage biotechnology company engaged in developing and commercializing treatments aimed at serious immunological diseases. Their portfolio includes atacicept, a fusion protein undergoing clinical trials for immunoglobulin A nephropathy and Phase II trials for lupus nephritis. Another significant development in their pipeline is MAU868, a monoclonal antibody targeting the BK virus in transplant patients. The company is headquartered in Brisbane, California, and its shares are listed on the NASDAQ.